Ipilimumab in the real world: The UK expanded access programme experience in previously treated advanced melanoma patients

Melanoma Research

Volumn 25, Issue 5, 2015, Pages 432-442

  Ahmad, Saif S ^a   Qian, Wendi ^a   Ellis, Sarah ^b   Mason, Elaine ^c   Khattak, Muhammad A ^d   Gupta, Avinash ^e   Shaw, Heather ^f   Quinton, Amy ^g   Kovarikova, Jarmila ^h   Thillai, Kiruthikah ⁱ   Rao, Ankit ^j   Board, Ruth ^k   Nobes, Jenny ^l   Dalgleish, Angus ^m   Grumett, Simon ^j   Maraveyas, Anthony ⁿ   Danson, Sarah ^o   Talbot, Toby ^p   Harries, Mark ⁱ   Marples, Maria ^q   Plummer, Ruth ^h   Kumar, Satish ^g   Nathan, Paul ^f   Middleton, Mark R ^e   Larkin, James ^d   Lorigan, Paul ^c   Wheater, Matthew ^b   Ottensmeier, Christian H ^b   Corrie, Pippa G ^a   more..

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c Department of Medical Oncology ^*  (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^f MOUNT VERNON HOSPITAL   (United Kingdom)

^g VELINDRE CANCER CENTRE   (United Kingdom)

^h Northern Centre for Cancer Care   (United Kingdom)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^j ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^k ROYAL PRESTON HOSPITAL   (United Kingdom)

^l NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^m ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

ⁿ CASTLE HILL HOSPITAL   (United Kingdom)

^o UNIVERSITY OF SHEFFIELD   (United Kingdom)

^p ROYAL CORNWALL HOSPITAL   (United Kingdom)

^q ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

expanded access programme; ipilimumab; metastatic melanoma; treatment outcomes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; IPILIMUMAB; LACTATE DEHYDROGENASE; STEROID; CANCER VACCINE; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASEPTIC MENINGITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BRAIN METASTASIS; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PRACTICE; COMPASSIONATE USE; CONTROLLED STUDY; COUGHING; CUTANEOUS MELANOMA; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HYPOPHYSITIS; INAPPROPRIATE VASOPRESSIN SECRETION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MIDDLE AGED; MUCOSAL MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PATIENT CODING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; STEROID THERAPY; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT DURATION; UNITED KINGDOM; UVEA MELANOMA; UVEITIS; DISEASE COURSE; EPIDEMIOLOGY; EUROPE; HEALTH CARE DELIVERY; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SALVAGE THERAPY; SKIN NEOPLASMS; STANDARDS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CANCER VACCINES; DISEASE PROGRESSION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; UNITED KINGDOM;

EID: 84941789707     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000185     Document Type: Article

References (23)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
2. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
3. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889-1894.
4. Chasset F, Pages C, Biard L, Roux J, Sidina I, Madelaine I, et al. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. Eur J Dermatol 2015; 25:36-44.
5. Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014; 12:116.
6. Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63:449-458.
7. Berrocal A, Arance A, Lopez Martin JA, Soriano V, Munõz E, Alonso L, et al. Spanish Melanoma Group. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Res 2014; 24:577-583.
8. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013; 24:2911-2915.
9. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095.
10. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014; 15:436-444.
11. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an openlabel, phase 2 trial. Lancet Oncol 2012; 13:459-465.
12. Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, Mortier L, Bedane C, Girard C, et al. Ipilimumab in melanoma patients with brain metastasis: a retrospective multicentre evaluation of thirty-eight patients. Acta Derm Venereol 2014; 94:45-49.
13. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116:1767-1775.
14. Wiater K, Switaj T, Mackiewicz J, Kalinka-Warzocha E, Wojtukiewicz M, Szambora P, et al. Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Contemp Oncol (Pozn) 2013; 17:257-262.
15. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013; 24:1697-1703.
16. Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Liénard D, et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013; 36:215-222.
17. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62:1021-1028.
18. Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, et al. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res 2013; 32:82.
19. Shapira-Frommer R, Stephen F, Ben-Ami E, Hamburger T, Markel G, Ospovat I, et al. Ipilimumab for advanced, refractory melanoma: a report of the Israeli cohort of expanded access program [Abstract]. J Clin Oncol 2013; 31:e20039.
20. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014; 63:675-683.
21. Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer 2014; 110:1721-1726.
22. Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 2014; 118:109-116.
23. Alexander M, Mellor JD, McArthur G, Kee D. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Med J Aust 2014; 201:49-53.